Second, though Pin1 inhibition has translational potential, no Pin1 inhibitors have entered clinical trials, with unresolved challenges like in vivo delivery efficiency, long-term safety, and patient-specific responsiveness in CRC (53). This evidence concerns the gene PIN1 and colorectal carcinoma.